MRNS
Income statement / Annual
Last year (2023), Marinus Pharmaceuticals, Inc.'s total revenue was $30.99 M,
an increase of 21.63% from the previous year.
In 2023, Marinus Pharmaceuticals, Inc.'s net income was -$141.41 M.
See Marinus Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$30.99 M |
$25.48 M |
$15.35 M |
$1.72 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$1.93 M
|
$340.00 K
|
$1.48 M
|
$50.51 M
|
$503.00 K
|
$127.00 K
|
$126.00 K
|
$23.00 K
|
$11.00 K
|
$0.00
|
| Gross Profit |
$29.06 M
|
$25.14 M
|
$13.87 M
|
-$48.79 M
|
-$503.00 K
|
-$127.00 K
|
-$126.00 K
|
-$23.00 K
|
-$11.00 K
|
$0.00
|
| Gross Profit Ratio |
0.94
|
0.99
|
0.9
|
-28.4
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$99.39 M
|
$79.91 M
|
$73.52 M
|
$51.11 M
|
$42.97 M
|
$28.39 M
|
$12.38 M
|
$22.01 M
|
$18.92 M
|
$8.69 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$37.28 M
|
$18.55 M
|
$11.46 M
|
$8.79 M
|
$6.67 M
|
$6.24 M
|
$5.52 M
|
$3.23 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$61.15 M
|
$56.85 M
|
$37.28 M
|
$18.55 M
|
$11.46 M
|
$8.79 M
|
$6.67 M
|
$6.24 M
|
$5.52 M
|
$3.23 M
|
| Other Expenses |
$0.00
|
$1.17 M
|
$657.00 K
|
-$37.00 K
|
-$53.00 K
|
-$1.00 K
|
-$20.00 K
|
-$65.00 K
|
-$7.00 K
|
$0.00
|
| Operating Expenses |
$160.54 M
|
$137.93 M
|
$110.80 M
|
$69.66 M
|
$54.42 M
|
$37.18 M
|
$19.04 M
|
$28.24 M
|
$24.43 M
|
$11.92 M
|
| Cost And Expenses |
$162.47 M
|
$138.27 M
|
$112.28 M
|
$69.66 M
|
$54.42 M
|
$37.18 M
|
$19.04 M
|
$28.24 M
|
$24.43 M
|
$11.92 M
|
| Interest Income |
$8.11 M
|
$2.35 M
|
$80.00 K
|
$499.00 K
|
$354.00 K
|
$454.00 K
|
$324.00 K
|
$128.00 K
|
$64.00 K
|
$12.00 K
|
| Interest Expense |
$16.90 M
|
$10.67 M
|
$2.58 M
|
$0.00
|
$0.00
|
$0.00
|
$159.00 K
|
$464.00 K
|
$475.00 K
|
$117.00 K
|
| Depreciation & Amortization |
$551.00 K
|
$669.00 K
|
$667.00 K
|
$598.00 K
|
$503.00 K
|
$127.00 K
|
$126.00 K
|
$23.00 K
|
$11.00 K
|
$5.00 K
|
| EBITDA |
-$125.50 M |
-$5.09 M |
-$95.53 M |
-$66.88 M |
-$53.92 M |
-$36.60 M |
-$18.61 M |
-$28.16 M |
-$24.36 M |
-$10.71 M |
| EBITDA Ratio |
-4.05
|
-0.2
|
-6.23
|
-38.93
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-4.24
|
-4.43
|
-6.32
|
-39.54
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$11.46 M
|
$96.36 M
|
-$1.85 M
|
$462.00 K
|
$301.00 K
|
$453.00 K
|
$145.00 K
|
-$401.00 K
|
-$418.00 K
|
$1.09 M
|
| Income Before Tax |
-$142.94 M
|
-$16.43 M
|
-$98.78 M
|
-$67.48 M
|
-$54.12 M
|
-$36.73 M
|
-$18.90 M
|
-$28.64 M
|
-$24.85 M
|
-$10.83 M
|
| Income Before Tax Ratio |
-4.61
|
-0.64
|
-6.44
|
-39.28
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$1.54 M
|
$3.39 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$13.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$141.41 M
|
-$19.82 M
|
-$101.66 M
|
-$66.64 M
|
-$53.77 M
|
-$36.73 M
|
-$18.90 M
|
-$28.64 M
|
-$24.85 M
|
-$10.83 M
|
| Net Income Ratio |
-4.56
|
-0.78
|
-6.62
|
-38.79
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.63 |
-0.51 |
-2.77 |
-2.44 |
-3.95 |
-3.59 |
-3.21 |
-5.88 |
-6.66 |
-7.04 |
| EPS Diluted |
-2.63 |
-0.51 |
-2.77 |
-2.44 |
-3.95 |
-3.59 |
-3.21 |
-5.88 |
-6.66 |
-7.04 |
| Weighted Average Shares Out |
$53.75 M
|
$39.07 M
|
$36.70 M
|
$27.27 M
|
$13.63 M
|
$10.22 M
|
$5.89 M
|
$4.87 M
|
$3.73 M
|
$1.54 M
|
| Weighted Average Shares Out Diluted |
$53.75 M
|
$39.07 M
|
$36.70 M
|
$27.27 M
|
$13.63 M
|
$10.22 M
|
$5.89 M
|
$4.87 M
|
$3.73 M
|
$1.54 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
